New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...